151 related articles for article (PubMed ID: 38447700)
21. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
[TBL] [Abstract][Full Text] [Related]
23. Bimekizumab for the treatment of psoriasis.
Thapar M; Patel M; Gordon K
Immunotherapy; 2024 Apr; 16(7):431-446. PubMed ID: 38506262
[TBL] [Abstract][Full Text] [Related]
24. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
25. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials.
Wang Y; Li S; Bai J; Cai X; Tang S; Lin P; Sun Q; Qiao J; Fang H
Ther Adv Chronic Dis; 2023; 14():20406223231163110. PubMed ID: 37051072
[TBL] [Abstract][Full Text] [Related]
26. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
27. Review of bimekizumab in the treatment of psoriasis.
Koppu S; Singh R; Kaur K; Feldman SR
Hum Vaccin Immunother; 2022 Nov; 18(6):2119767. PubMed ID: 36094828
[TBL] [Abstract][Full Text] [Related]
28. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
[TBL] [Abstract][Full Text] [Related]
29. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
Gotesman RD; Vender R
Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
[TBL] [Abstract][Full Text] [Related]
30. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.
Ruggiero A; Potestio L; Camela E; Fabbrocini G; Megna M
Psoriasis (Auckl); 2022; 12():127-137. PubMed ID: 35707807
[TBL] [Abstract][Full Text] [Related]
31. Bimekizumab for the Treatment of Psoriasis.
Freitas E; Blauvelt A; Torres T
Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
[TBL] [Abstract][Full Text] [Related]
32. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
33. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M
Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D; Kimball AB
Br J Dermatol; 2023 Jan; 188(1):22-31. PubMed ID: 36689515
[TBL] [Abstract][Full Text] [Related]
35. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Strober B; Paul C; Blauvelt A; Thaçi D; Puig L; Lebwohl M; White K; Vanvoorden V; Deherder D; Gomez NN; Eyerich K
J Am Acad Dermatol; 2023 Sep; 89(3):486-495. PubMed ID: 37182701
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
Armstrong A; Fahrbach K; Leonardi C; Augustin M; Neupane B; Kazmierska P; Betts M; Freitag A; Kiri S; Taieb V; Slim M; Gomez NN; Warren RB
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1777-1792. PubMed ID: 35798920
[TBL] [Abstract][Full Text] [Related]
37. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
38. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
39. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Rosmarin D; Lebwohl M; Peterson L; Madden C; de Cuyper D; Davies O; Thaçi D
Br J Dermatol; 2024 Mar; 190(4):477-485. PubMed ID: 37950894
[TBL] [Abstract][Full Text] [Related]
40. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
